






**Figure S1.** Kaplan Meier survival curves for all-cause death over 365 days stratified by CCS < 2, CCS = 2, and CCS > 2.



**Figure S2.** Kaplan Meier survival curves for death/MI over 365 days stratified by CCS < 2, CCS = 2, and CCS > 2.



**Figure S3.** Kaplan Meier survival curves for MACE over 365 days stratified by CCS < 2, CCS = 2, and CCS >2.

**Table S1.** Comparison of baseline characteristics and crude outcomes by CCS (< 2, 2, > 2) for patients with a diagnosis of chest pain discharged home from the ED from Cohort1.

| Variable                                                                        | CCS<2           | CCS=2           | CCS>2           | P-Value |
|---------------------------------------------------------------------------------|-----------------|-----------------|-----------------|---------|
|                                                                                 | N=456           | N=457           | N=454           |         |
| Age, Median (IQR)                                                               | 53 (48-62)      | 65 (54-76)      | 76 (66-82)      | <.001   |
| Sex (F)                                                                         | 260<br>(57.0%)  | 285<br>(62.4%)  | 232<br>(51.1%)  | 0.003   |
| <b>Past medical history, n (%)</b>                                              |                 |                 |                 |         |
| Arrhythmia                                                                      | 16 (3.5%)       | 43 (9.4%)       | 101<br>(22.2%)  | <.001   |
| Congestive heart failure                                                        | 24 (5.3%)       | 41 (9.0%)       | 123<br>(27.1%)  | <.001   |
| Chronic obstructive pulmonary disorder                                          | 89 (19.5%)      | 104<br>(22.8%)  | 126<br>(27.8%)  | 0.013   |
| Diabetes                                                                        | 64 (14.0%)      | 129<br>(28.2%)  | 190<br>(41.9%)  | <.001   |
| Hypertension                                                                    | 192<br>(42.1%)  | 309<br>(67.6%)  | 365<br>(80.4%)  | <.001   |
| Myocardial infarction                                                           | 20 (4.4%)       | 28 (6.1%)       | 66 (14.5%)      | <.001   |
| Peripheral vascular disease                                                     | 8 (1.8%)        | 25 (5.5%)       | 69 (15.2%)      | <.001   |
| Renal disease                                                                   | <=5             | 7 (1.5%)        | 25 (5.5%)       | <.001   |
| Stroke                                                                          | 9 (2.0%)        | 6 (1.3%)        | 17 (3.7%)       | 0.043   |
| Unstable angina                                                                 | 11 (2.4%)       | 26 (5.7%)       | 24 (5.3%)       | 0.033   |
| Percutaneous coronary intervention                                              | 10 (2.2%)       | 20 (4.4%)       | 23 (5.1%)       | 0.064   |
| Coronary artery bypass grafting                                                 | <=5             | 11 (2.4%)       | 15 (3.3%)       | 0.008   |
| Echocardiography                                                                | 168<br>(36.8%)  | 233<br>(51.0%)  | 311<br>(68.5%)  | <.001   |
| Cardiac catheterization                                                         | 32 (7.0%)       | 62 (13.6%)      | 89 (19.6%)      | <.001   |
| Permanent pacemaker                                                             | <=5             | <=5             | 16 (3.5%)       | <.001   |
| Implantable cardioverter-defibrillator                                          | <=5             | <=5             | 8 (1.8%)        | 0.005   |
| Stress testing                                                                  | 137<br>(30.0%)  | 165<br>(36.1%)  | 159<br>(35.0%)  | 0.119   |
| <b>Physician follow-up 30 days following ED discharge, n (%)</b>                |                 |                 |                 |         |
| Cardiology                                                                      | 29 (6.4%)       | 45 (9.8%)       | 63 (13.9%)      | 0.001   |
| General/Family physician                                                        | 224<br>(49.1%)  | 234<br>(51.2%)  | 230<br>(50.7%)  |         |
| None                                                                            | 203<br>(44.5%)  | 178<br>(38.9%)  | 161<br>(35.5%)  |         |
| <b>All- cause mortality or hospitalization for MI/angina, n (%)</b>             |                 |                 |                 |         |
| 30 days                                                                         | <=5             | <=5             | 8 (1.8%)        | 0.055   |
| 90 days                                                                         | <=5             | <=5             | 21 (4.6%)       | <.001   |
| 1 year                                                                          | 11 (2.4%)       | 26 (5.7%)       | 60 (13.2%)      | <.001   |
| <b>Laboratory Values</b>                                                        |                 |                 |                 |         |
| Serum creatinine, umol/L, Median (IQR)                                          | 70 (64-77)      | 76 (69-89)      | 90 (75-114)     | <.001   |
| Glucose, mmol/L, Mean $\pm$ SD                                                  | 5.74 $\pm$ 1.80 | 6.92 $\pm$ 2.84 | 7.56 $\pm$ 2.74 | <.001   |
| hs-cTnI, ng/L, Median (IQR)                                                     | 2 (1-3)         | 3 (2-5)         | 9 (6-16)        | <.001   |
| Estimated glomerular filtration rate, mL/min/1.73 m <sup>2</sup> , Median (IQR) | 94 (86-101)     | 78 (66-86)      | 64 (47-78)      | <.001   |

**Table S2.** Comparison of baseline characteristics and crude outcomes by CCS (< 2, 2, > 2) for patients with a diagnosis of chest pain discharged home from the ED from Cohort2.

| Variable                                                                        | CCS<2            | CCS=2            | CCS>2            | P-Value |
|---------------------------------------------------------------------------------|------------------|------------------|------------------|---------|
|                                                                                 | N=5,948          | N=3,879          | N=3,482          |         |
| Age, Median (IQR)                                                               | 52 (46-59)       | 61 (52-71)       | 74 (63-82)       | <.001   |
| Sex (F)                                                                         | 3,545<br>(59.6%) | 2,111<br>(54.4%) | 1,658<br>(47.6%) | <.001   |
| <b>Past medical history, n (%)</b>                                              |                  |                  |                  |         |
| Arrhythmia                                                                      | 84 (1.4%)        | 178 (4.6%)       | 477 (13.7%)      | <.001   |
| Congestive heart failure                                                        | 105 (1.8%)       | 185 (4.8%)       | 718 (20.6%)      | <.001   |
| Chronic obstructive pulmonary disorder                                          | 664 (11.2%)      | 668 (17.2%)      | 916 (26.3%)      | <.001   |
| Diabetes                                                                        | 755 (12.7%)      | 838 (21.6%)      | 1,369<br>(39.3%) | <.001   |
| Hypertension                                                                    | 2,116<br>(35.6%) | 2,163<br>(55.8%) | 2,773<br>(79.6%) | <.001   |
| Myocardial infarction                                                           | 151 (2.5%)       | 181 (4.7%)       | 425 (12.2%)      | <.001   |
| Peripheral vascular disease                                                     | 62 (1.0%)        | 104 (2.7%)       | 446 (12.8%)      | <.001   |
| Renal disease                                                                   | <=5              | 8 (0.2%)         | 146 (4.2%)       | <.001   |
| Stroke                                                                          | 26 (0.4%)        | 25 (0.6%)        | 71 (2.0%)        | <.001   |
| Unstable angina                                                                 | 68 (1.1%)        | 128 (3.3%)       | 262 (7.5%)       | <.001   |
| Percutaneous coronary intervention                                              | 180 (3.0%)       | 223 (5.7%)       | 352 (10.1%)      | <.001   |
| Coronary artery bypass grafting                                                 | 26 (0.4%)        | 50 (1.3%)        | 100 (2.9%)       | <.001   |
| Echocardiography                                                                | 2,083<br>(35.0%) | 1,810<br>(46.7%) | 2,266<br>(65.1%) | <.001   |
| Cardiac catheterization                                                         | 363 (6.1%)       | 442 (11.4%)      | 730 (21.0%)      | <.001   |
| Permanent pacemaker                                                             | <=5              | 24 (0.6%)        | 54 (1.6%)        | <.001   |
| Implantable cardioverter-defibrillator                                          | <=5              | 6 (0.2%)         | 12 (0.3%)        | <.001   |
| Stress testing                                                                  | 1,871<br>(31.5%) | 1,623<br>(41.8%) | 1,663<br>(47.8%) | <.001   |
| <b>Physician follow-up 30 days following ED discharge, n (%)</b>                |                  |                  |                  |         |
| Cardiology                                                                      | 1,738<br>(29.2%) | 1,480<br>(38.2%) | 1,535<br>(44.1%) | <.001   |
| General/Family physician                                                        | 2,134<br>(35.9%) | 1,318<br>(34.0%) | 1,244<br>(35.7%) |         |
| None                                                                            | 2,076<br>(34.9%) | 1,081<br>(27.9%) | 703 (20.2%)      |         |
| <b>All- cause mortality or hospitalization for MI/angina, n (%)</b>             |                  |                  |                  |         |
| 30 days                                                                         | 17 (0.3%)        | 33 (0.9%)        | 84 (2.4%)        | <.001   |
| 90 days                                                                         | 23 (0.4%)        | 43 (1.1%)        | 161 (4.6%)       | <.001   |
| 365 days                                                                        | 71 (1.2%)        | 120 (3.1%)       | 377 (10.8%)      | <.001   |
| <b>Laboratory Values</b>                                                        |                  |                  |                  |         |
| Creatinine, umol/L, Median (IQR)                                                | 66 (58-77)       | 77 (68-89)       | 89 (75-107)      | <.001   |
| Glucose, mmol/L, Mean $\pm$ SD                                                  | 5.88 $\pm$ 1.84  | 6.68 $\pm$ 2.35  | 7.49 $\pm$ 2.94  | <.001   |
| hs-cTnT, ng/L, Median (IQR)                                                     | 5 (3-6)          | 7 (5-13)         | 14 (12-24)       | <.001   |
| Estimated glomerular filtration rate, mL/min/1.73 m <sup>2</sup> , Median (IQR) | 97 (91-104)      | 81 (71-89)       | 67 (51-80)       | <.001   |

**Table S3.** Cox proportional hazard model estimates for CCS, all-cause mortality plus hospitalization for MI/UA for Cohort 1 with hs-cTnI.

| Time of outcome assessment | Model* | CCS category | Hazard ratio (95% CI) |
|----------------------------|--------|--------------|-----------------------|
| 30 days                    | 1      | CCS < 2      | 0.25 (0.03-2.24)      |
|                            |        | CCS > 2      | 2.02 (0.61-6.72)      |
|                            | 2      | CCS < 2      | 0.51 (0.05-4.91)      |
|                            |        | CCS > 2      | 1.24 (0.35-4.33)      |
|                            | 3      | CCS < 2      | 0.57 (0.06-5.49)      |
|                            |        | CCS > 2      | 1.34 (0.38-4.76)      |
| 90 days                    | 1      | CCS < 2      | 1.00 (0.29-3.45)      |
|                            |        | CCS > 2      | 4.29 (1.62-11.38)     |
|                            | 2      | CCS < 2      | 1.85 (0.51-6.73)      |
|                            |        | CCS > 2      | 2.82 (1.03-7.71)      |
|                            | 3      | CCS < 2      | 1.96 (0.53-7.21)      |
|                            |        | CCS > 2      | 2.48 (0.89-6.86)      |
| 365 days                   | 1      | CCS < 2      | 0.42 (0.21-0.85)      |
|                            |        | CCS > 2      | 2.42 (1.53-3.84)      |
|                            | 2      | CCS < 2      | 0.77 (0.37-1.61)      |
|                            |        | CCS > 2      | 1.55 (0.96-2.51)      |
|                            | 3      | CCS < 2      | 0.83 (0.39-1.74)      |
|                            |        | CCS > 2      | 1.32 (0.81-2.16)      |

\* Model 1 unadjusted; Model 2 adjusted for age and sex; Model 3 adjusted for age, sex, prior history of arrhythmia, heart failure, diabetes, hypertension, MI, peripheral vascular disease, renal disease, stroke and UA. Reference group is CCS = 2.

**Table S4.** Cox proportional hazard model estimates for CCS, all-cause mortality plus hospitalization for MI/UA for Cohort 2 with hs-cTnT.

| Time of outcome assessment | Model* | CCS category | Hazard ratio (95% CI) |
|----------------------------|--------|--------------|-----------------------|
| 30 days                    | 1      | CCS < 2      | 0.34 (0.19-0.60)      |
|                            |        | CCS > 2      | 2.86 (1.91-4.28)      |
|                            | 2      | CCS < 2      | 0.37 (0.21-0.68)      |
|                            |        | CCS > 2      | 2.49 (1.62-3.84)      |
|                            | 3      | CCS < 2      | 0.40 (0.22-0.72)      |
|                            |        | CCS > 2      | 2.14 (1.37-3.34)      |
| 90 days                    | 1      | CCS < 2      | 0.35 (0.21-0.58)      |
|                            |        | CCS > 2      | 4.24 (3.03-5.93)      |
|                            | 2      | CCS < 2      | 0.42 (0.25-0.70)      |
|                            |        | CCS > 2      | 3.37 (2.36-4.83)      |
|                            | 3      | CCS < 2      | 0.43 (0.26-0.73)      |
|                            |        | CCS > 2      | 2.87 (1.99-4.16)      |
| 1 year                     | 1      | CCS < 2      | 0.38 (0.28-0.51)      |
|                            |        | CCS > 2      | 3.65 (2.97-4.48)      |
|                            | 2      | CCS < 2      | 0.55 (0.41-0.75)      |
|                            |        | CCS > 2      | 2.38 (1.91-2.96)      |
|                            | 3      | CCS < 2      | 0.58 (0.43-0.78)      |
|                            |        | CCS > 2      | 1.89 (1.50-2.37)      |

\* Model 1 unadjusted; Model 2 adjusted for age and sex; Model 3 adjusted for age, sex, prior history of arrhythmia, heart failure, diabetes, hypertension, MI, peripheral vascular disease, renal disease, stroke and UA. Reference group is CCS =2.

**Table S5.** Cox proportional hazard model estimates (model 3) for the secondary outcome of MACE (defined as the composite of death/MI/UA/PCI or CABG) at 30 days, 90 days, and 365 days with CCS < 2 as the reference group for the study population (n=14,676).

| <b>Time of outcome assessment</b> | <b>CCS category</b> | <b>Hazard ratio (95% CI)*</b> |
|-----------------------------------|---------------------|-------------------------------|
| 30 days                           | CCS = 2             | 2.83 (1.79-4.47)              |
|                                   | CCS > 2             | 4.91 (3.04-7.91)              |
| 90 days                           | CCS = 2             | 2.26 (1.58-3.22)              |
|                                   | CCS > 2             | 5.27 (3.69-7.54)              |
| 365 days                          | CCS = 2             | 1.74 (1.38-2.21)              |
|                                   | CCS > 2             | 3.19 (2.51-4.07)              |

\* all p-values are <0.01.